Point Therapeutics: talabostat stimulates cytokines against cancer

By Lisa Kerner

Charlotte, N.C., Sept. 14 - Point Therapeutics, Inc. said its anti-cancer agent talabostat has shown the ability to enhance the body's natural defenses against cancer (immunostimulation) by stimulating key cytokines, including IL-1 alpha.

"The very nature of talabostat's dual mechanism of action through both immunostimulation and FAP inhibition speaks to its potential versatility as a targeted agent with broad utility in several different cancers," Charles Dinarello, lead investigator, said in a company news release.

Data from a study of talabostat was presented at the American Association of Cancer Research Annual Meeting and International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Chicago.

Point is a Boston-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.